Cargando…

FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function

Disclosure: B.T. Legvold: None. A. Zhang: None. K.M. Utzschneider: None. M.K. Rhee: None. L.R. Staimez: None. K.A. Easley: None. M.M. Van Greevenbroek: None. C.J. Van Der Kallen: None. C.G. Schalkwijk: None. C.D. Stehouwer: None. L.S. Phillips: None. Development of diabetes (DM) is attributed to red...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas Legvold, Brian, Zhang, Amanda, Marie Utzschneider, Kristina, Kyung Rhee, Mary, Staimez, Lisa R, Easley, Kirk A, Van Greevenbroek, Marleen M J, Van Der Kallen, Carla J H, Schalkwijk, Casper G, Stehouwer, Coen D A, Phillips, Lawrence S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555305/
http://dx.doi.org/10.1210/jendso/bvad114.837
_version_ 1785116625064689664
author Thomas Legvold, Brian
Zhang, Amanda
Marie Utzschneider, Kristina
Kyung Rhee, Mary
Staimez, Lisa R
Easley, Kirk A
Van Greevenbroek, Marleen M J
Van Der Kallen, Carla J H
Schalkwijk, Casper G
Stehouwer, Coen D A
Phillips, Lawrence S
author_facet Thomas Legvold, Brian
Zhang, Amanda
Marie Utzschneider, Kristina
Kyung Rhee, Mary
Staimez, Lisa R
Easley, Kirk A
Van Greevenbroek, Marleen M J
Van Der Kallen, Carla J H
Schalkwijk, Casper G
Stehouwer, Coen D A
Phillips, Lawrence S
author_sort Thomas Legvold, Brian
collection PubMed
description Disclosure: B.T. Legvold: None. A. Zhang: None. K.M. Utzschneider: None. M.K. Rhee: None. L.R. Staimez: None. K.A. Easley: None. M.M. Van Greevenbroek: None. C.J. Van Der Kallen: None. C.G. Schalkwijk: None. C.D. Stehouwer: None. L.S. Phillips: None. Development of diabetes (DM) is attributed to reduced β-cell function, but we lack a measure of β-cell function that is a good predictor of progression to diabetes, and sufficiently convenient and inexpensive for use in large studies. To determine if the 1-hour plasma glucose in a 75g oral glucose tolerance test (1hrOGTT) might serve this purpose, we examined (i) correlations with insulin secretion (insSEC) vs. action (insACT), (ii) prediction of progression from nonDM to DM, and (iii) sample size needed for a prospective trial. The Cohort study of Diabetes and Atherosclerosis Maastricht (CoDAM) included 362 participants with nonDM at baseline who were restudied after 7 years. Incident DM (n=54) was based on American Diabetes Association OGTT cutpoints; insACT included 1/[fasting ins] (I), HOMA2-S (H), and the modified Matsuda Index (M); and insSEC as OGTT Δins/Δglucose(0-30min) (ISI) and ΔCpep/Δglucose(0-30) (CpSI). Since β-cell function reflects insulin secretion relative to insulin action in each individual, we also assessed the disposition index (DI) as insSEC*insACT. (i) Spearman correlations: The 1hrOGTT was correlated with both the 0hrOGTT (0.54) and 2hrOGTT (0.64); weakly with insACT (I, H, and M as 0.31, 0.33, and 0.53, respectively); more strongly with insSEC (ISI and CpSI as 0.54 and 0.67, respectively); and most strongly with DI (ISI*M, CpSI*M, ISI*I, and CpSI*I as −0.89, −0.83, −0.77, and −0.73, respectively); correlations with DI including H were all weaker. (ii) Prediction of progression from nonDM to DM: The area under the receiver operating characteristic curve (ROC) for the 1hrOGTT was 0.84±0.02 (SE), while the ROCs with DI ISI*M, CpSI*M, ISI*I, CpSI*I, ISI*H, and CpSI*H were 0.86, 0.84, 0.85, 0.84, 0.85, and 0.85, respectively. There was no difference between the ROC with the 1hrOGTT and that of the DI models (all p >0.15), while the ROC with the 1hrOGTT was significantly higher than that with most other metrics. (iii) Sample size needed for use in a trial: A side-by-side, two-arm prospective study, with α=0.05 and 80% power to detect a 20% change in β-cell function, would require 26 subjects with the 1hrOGTT, vs. 228 subjects with DI ISI*M. The lower sample size needed reflects lower underlying variance: the coefficient of variation (CV) was 26.7% with the 1hrOGTT, while the CVs for DI ISI*M, CpSI*M, ISI*I, CpSI*I, ISI*H, and CpSI*H were 176.7%, 180.0%, 150.0%, 155.4%, 107.2%, and 90.0%, respectively. Conclusion: The 1-hour 75g OGTT plasma glucose is strongly correlated with the glucose disposition index, and comparable to the disposition index in predicting progression of nonDM to DM, but would require fewer subjects for statistical power in a prospective trial. Since the 1-hour OGTT glucose appears to provide performance similar or superior to more complex and labor-intensive methods, at a greatly reduced cost, consideration should be given to its use as a measure of β-cell function. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10555305
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105553052023-10-06 FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function Thomas Legvold, Brian Zhang, Amanda Marie Utzschneider, Kristina Kyung Rhee, Mary Staimez, Lisa R Easley, Kirk A Van Greevenbroek, Marleen M J Van Der Kallen, Carla J H Schalkwijk, Casper G Stehouwer, Coen D A Phillips, Lawrence S J Endocr Soc Diabetes And Glucose Metabolism Disclosure: B.T. Legvold: None. A. Zhang: None. K.M. Utzschneider: None. M.K. Rhee: None. L.R. Staimez: None. K.A. Easley: None. M.M. Van Greevenbroek: None. C.J. Van Der Kallen: None. C.G. Schalkwijk: None. C.D. Stehouwer: None. L.S. Phillips: None. Development of diabetes (DM) is attributed to reduced β-cell function, but we lack a measure of β-cell function that is a good predictor of progression to diabetes, and sufficiently convenient and inexpensive for use in large studies. To determine if the 1-hour plasma glucose in a 75g oral glucose tolerance test (1hrOGTT) might serve this purpose, we examined (i) correlations with insulin secretion (insSEC) vs. action (insACT), (ii) prediction of progression from nonDM to DM, and (iii) sample size needed for a prospective trial. The Cohort study of Diabetes and Atherosclerosis Maastricht (CoDAM) included 362 participants with nonDM at baseline who were restudied after 7 years. Incident DM (n=54) was based on American Diabetes Association OGTT cutpoints; insACT included 1/[fasting ins] (I), HOMA2-S (H), and the modified Matsuda Index (M); and insSEC as OGTT Δins/Δglucose(0-30min) (ISI) and ΔCpep/Δglucose(0-30) (CpSI). Since β-cell function reflects insulin secretion relative to insulin action in each individual, we also assessed the disposition index (DI) as insSEC*insACT. (i) Spearman correlations: The 1hrOGTT was correlated with both the 0hrOGTT (0.54) and 2hrOGTT (0.64); weakly with insACT (I, H, and M as 0.31, 0.33, and 0.53, respectively); more strongly with insSEC (ISI and CpSI as 0.54 and 0.67, respectively); and most strongly with DI (ISI*M, CpSI*M, ISI*I, and CpSI*I as −0.89, −0.83, −0.77, and −0.73, respectively); correlations with DI including H were all weaker. (ii) Prediction of progression from nonDM to DM: The area under the receiver operating characteristic curve (ROC) for the 1hrOGTT was 0.84±0.02 (SE), while the ROCs with DI ISI*M, CpSI*M, ISI*I, CpSI*I, ISI*H, and CpSI*H were 0.86, 0.84, 0.85, 0.84, 0.85, and 0.85, respectively. There was no difference between the ROC with the 1hrOGTT and that of the DI models (all p >0.15), while the ROC with the 1hrOGTT was significantly higher than that with most other metrics. (iii) Sample size needed for use in a trial: A side-by-side, two-arm prospective study, with α=0.05 and 80% power to detect a 20% change in β-cell function, would require 26 subjects with the 1hrOGTT, vs. 228 subjects with DI ISI*M. The lower sample size needed reflects lower underlying variance: the coefficient of variation (CV) was 26.7% with the 1hrOGTT, while the CVs for DI ISI*M, CpSI*M, ISI*I, CpSI*I, ISI*H, and CpSI*H were 176.7%, 180.0%, 150.0%, 155.4%, 107.2%, and 90.0%, respectively. Conclusion: The 1-hour 75g OGTT plasma glucose is strongly correlated with the glucose disposition index, and comparable to the disposition index in predicting progression of nonDM to DM, but would require fewer subjects for statistical power in a prospective trial. Since the 1-hour OGTT glucose appears to provide performance similar or superior to more complex and labor-intensive methods, at a greatly reduced cost, consideration should be given to its use as a measure of β-cell function. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10555305/ http://dx.doi.org/10.1210/jendso/bvad114.837 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diabetes And Glucose Metabolism
Thomas Legvold, Brian
Zhang, Amanda
Marie Utzschneider, Kristina
Kyung Rhee, Mary
Staimez, Lisa R
Easley, Kirk A
Van Greevenbroek, Marleen M J
Van Der Kallen, Carla J H
Schalkwijk, Casper G
Stehouwer, Coen D A
Phillips, Lawrence S
FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function
title FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function
title_full FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function
title_fullStr FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function
title_full_unstemmed FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function
title_short FRI615 The 1-Hour OGTT Plasma Glucose As A Biomarker Of β-cell Function
title_sort fri615 the 1-hour ogtt plasma glucose as a biomarker of β-cell function
topic Diabetes And Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555305/
http://dx.doi.org/10.1210/jendso/bvad114.837
work_keys_str_mv AT thomaslegvoldbrian fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT zhangamanda fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT marieutzschneiderkristina fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT kyungrheemary fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT staimezlisar fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT easleykirka fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT vangreevenbroekmarleenmj fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT vanderkallencarlajh fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT schalkwijkcasperg fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT stehouwercoenda fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction
AT phillipslawrences fri615the1hourogttplasmaglucoseasabiomarkerofbcellfunction